Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.70 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.70 |
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121501 | 1.00 | PTGS1 (0.70) | PTGS1GSTK1NOD1FOLH1ALOX15 | |
| SCHEMBL15420876 | 1.00 | PTGS1 (0.70) | PTGS1GSTK1NOD1FOLH1ALOX15 | |
| SCHEMBL121500 | 1.00 | PTGS1 (0.70) | PTGS1GSTK1NOD1FOLH1ALOX15 | |
| SCHEMBL2509561 | 1.00 | PTGS1 (0.70) | PTGS1GSTK1NOD1FOLH1ALOX15 | |
| SCHEMBL9347287 | 1.00 | PTGS1 (0.70) | PTGS1GSTK1NOD1FOLH1ALOX15 | |
| SCHEMBL27709907 | 1.00 | PTGS1 (0.70) | PTGS1GSTK1NOD1FOLH1ALOX15 | |
| Water SCHEMBL9548430 | 0.98 | PTGS1 (0.68) | PTGS1GSTK1NOD1FOLH1ALOX15 | |
| SCHEMBL29265136 | 0.98 | PTGS1 (0.68) | PTGS1GSTK1NOD1FOLH1ALOX15 | |
| SCHEMBL28993717 | 0.98 | PTGS1 (0.68) | PTGS1GSTK1NOD1FOLH1ALOX15 | |
| Cysteine SCHEMBL5355161 | 0.97 | PTGS1 (0.67) | PTGS1GSTK1NOD1FOLH1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9532961-B2 | Method and kit for administering γ-glutamyl-D-cysteine for the prevention of reperfusion injury following ischemic stroke | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2017-01-03 | — | — | US | claimed |
| US-20160193167-A9 | METHOD AND KIT FOR ADMINISTERING GAMMA-GLUTAMYL-D-CYSTEINE FOR THE PREVENTION OF REPERFUSION INJURY FOLLOWING ISCHEMIC STROKE | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2016-07-07 | — | — | US | claimed |
| US-20140024715-A1 | METHOD AND KIT FOR ADMIINISTERING GAMMA-GLUTAMYL-D-CYSTEINE FOR THE PREVENTION OF REPERFUSION INJURY FOLLOWING ISCHEMIC STROKE | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2014-01-23 | — | — | US | claimed |
| EP-3681521-A1 | METABOLOMIC REVISION OF MAMMALIAN INFANTS | Evolve Biosystems Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019055718-A1 | METABOLOMIC REVISION OF MAMMALIAN INFANTS | Evolve Biosystems, Inc. (US) | 2019-03-21 | — | — | WO | disclosed |
| EP-2305261-B1 | METHODS OF MANUFACTURING INTRAOCULAR IMPLANTS OF ALPHA-2 ADRENERGIC RECEPTOR AGONISTS | ALLERGAN INC (US) | 2018-09-26 | — | — | EP | disclosed |
| US-10064872-B2 | Oil-in-water method for making polymeric implants containing a hypotensive lipid | ALLERGAN, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20180153903-A1 | OIL-IN-WATER METHOD FOR MAKING POLYMERIC IMPLANTS CONTAINING A HYPOTENSIVE LIPID | ALLERGAN, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9532961-B2 | Method and kit for administering γ-glutamyl-D-cysteine for the prevention of reperfusion injury following ischemic stroke | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2017-01-03 | — | — | US | disclosed |
| US-9532961-B2 | Method and kit for administering γ-glutamyl-D-cysteine for the prevention of reperfusion injury following ischemic stroke | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2017-01-03 | — | — | US | disclosed |
| US-9532961-B2 | Method and kit for administering γ-glutamyl-D-cysteine for the prevention of reperfusion injury following ischemic stroke | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160193167-A9 | METHOD AND KIT FOR ADMINISTERING GAMMA-GLUTAMYL-D-CYSTEINE FOR THE PREVENTION OF REPERFUSION INJURY FOLLOWING ISCHEMIC STROKE | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160193167-A9 | METHOD AND KIT FOR ADMINISTERING GAMMA-GLUTAMYL-D-CYSTEINE FOR THE PREVENTION OF REPERFUSION INJURY FOLLOWING ISCHEMIC STROKE | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2016-07-07 | — | — | US | disclosed |
| US-20140024715-A1 | METHOD AND KIT FOR ADMIINISTERING GAMMA-GLUTAMYL-D-CYSTEINE FOR THE PREVENTION OF REPERFUSION INJURY FOLLOWING ISCHEMIC STROKE | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024715-A1 | METHOD AND KIT FOR ADMIINISTERING GAMMA-GLUTAMYL-D-CYSTEINE FOR THE PREVENTION OF REPERFUSION INJURY FOLLOWING ISCHEMIC STROKE | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2014-01-23 | — | — | US | disclosed |
| CN-101402921-B | Method for producing gamma-glutamylcycteine | AJINOMOTO KK | 2012-11-14 | — | — | CN | disclosed |
| CN-101402921-A | Method for producing gamma-glutamylcycteine | AJINOMOTO KK (JP) | 2009-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180153903-A1 | OIL-IN-WATER METHOD FOR MAKING POLYMERIC IMPLANTS CONTAINING A HYPOTENSIVE LIPID | MYOC, PHOSPHO1, MGLL | PTGS1 33/4885GSTK1 2648/4885NOD1 4108/4885 |
| US-10064872-B2 | Oil-in-water method for making polymeric implants containing a hypotensive lipid | MYOC, PHOSPHO1, MGLL | PTGS1 33/4885GSTK1 2648/4885NOD1 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.